Previous research has demonstrated a strong correlation between aberrant activation of the MAPK pathway and LCH development, affecting approximately 85% of pediatric patients with the disease.15,16 Specifically, BRAF V600E mutations are observed in approximately 60% of pediatric LCH cases.17,18 The BRAF V600E mutation, which manifests at various stages of cellular development, occurs at different developmental stages in hematopoietic cells, indirectly affecting the clinical manifestations and typing. The gene discussed is BRAF; the disease is Langerhans cell histiocytosis.